Middle East & Africa Organoids Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The organoids market in the Middle East and Africa is projected to grow significantly, reaching approximately US$ 289.76 million by 2031, up from US$ 77.94 million in 2023, with a compound annual growth rate (CAGR) of 17.8% during this period.

Executive Summary and Market Analysis

The market is divided into several regions, including the UAE, South Africa, Saudi Arabia, and the Rest of the Middle East and Africa. The growth in this sector is primarily driven by increased research into cancer and genetic mutations, the rising adoption of disease modeling techniques, and advancements made by companies in organoid technology.

Market Segmentation

The Middle East and Africa organoids market can be analyzed through various segments: type, application, source, offering, and method.

Type: The market is categorized into organoids derived from the intestine, liver, stomach, pancreas, lung, brain, kidney, and others. In 2023, the intestine organoids held the largest market share.
Application: The applications of organoids include developmental biology, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery, personalized medicine, and others. Developmental biology applications dominated the market in 2023.
Source: The market is divided into organoids derived from pluripotent stem cells and organ-specific adult stem cells, with pluripotent stem cells accounting for a larger share in 2023.
Offering: This segment includes instruments, consumables, and services, with consumables leading the market in 2023. Instruments are further divided into devices and equipment, while consumables include sensors and other items.
Method: The methods used to create organoids include micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion techniques, and others. The hanging drop method was the most prevalent in 2023.

Market Outlook

Organoids are 3D structures derived from stem cells that replicate the architecture and function of real organs. This innovative technology has facilitated the development of numerous human cancer models, allowing for the indefinite expansion of organoids from tumor tissues of cancer patients. Techniques such as CRISPR enable the modification of organoids to create cancer models by introducing specific genetic changes. Tumor organoids, when combined with immune cells and fibroblasts, can simulate a cancer microenvironment, which is valuable for immuno-oncology research.

Recent advancements in organoid technology have made it possible to create patient-specific 3D cultures from tumor biopsies, enhancing personalized medicine approaches. Organoids have been successfully generated from various cancers, including breast, bladder, colon, prostate, pancreas, and liver cancers, providing insights into these diseases. The introduction of tumoroid lines in vitro is paving the way for new applications in drug discovery and cancer research, with 3D cultures offering advantages over traditional 2D cell lines.

Research indicates that tumoroid culturing is effective for collecting diverse cancer subtypes from patients. As organoids can be derived from single cancer cells, they are increasingly used to replicate intratumor differentiation in laboratory settings. Companies are also developing biobanks for storing biological samples, including tumors. For example, OrganoidBase by Crown Bioscience features 342 tumor organoid models derived from patient-derived xenograft (PDX) models, providing extensive data on drug responses and genomic analyses.

Country Insights

The organoids market in the Middle East and Africa includes key countries such as Saudi Arabia, South Africa, and the UAE, with Saudi Arabia holding the largest market share in 2023. The country has seen a rise in regenerative medicine research, focusing on chronic diseases and potential treatments for metabolic disorders and cancer through cellular therapies. Government initiatives and collaborations among key players and research institutions are expected to enhance the adoption of organoid technologies in Saudi Arabia.

Saudi Arabia has made significant strides in stem cell donation, becoming the first Arab nation to register over 10,000 stem cell donors in 2015. This growth in stem cell research is anticipated to support the organoids market, especially in light of the increasing incidence of chronic diseases such as multiple sclerosis and cancer.

Company Profiles

Key players in the organoids market include STEMCELL Technologies Inc., Molecular Devices, Hubrecht Organoid Technology, Definigen, Organoid Therapeutics, Thermo Fisher Scientific Inc., Corning Inc., Merck KGaA, InSphero, ACRO Biosystems, Bio-Techne Corp, and others. These companies are pursuing strategies such as expansion, product innovation, and mergers to enhance their market presence and offer cutting-edge products.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa organoids market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa organoids market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the organoids market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution. Show more